NCT00363519 - Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus | Biotech Hunter

Enrollment

195

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

January 31, 2008

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Placebo

Double-blind period (12 wk); placebo QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD

DRUG

Sitagliptin phosphate

Double-blind period (12 wk); 50 mg QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD

Trial Locations (8)

Unknown

Chugoku Region, Chugoku

Chubu Region, Chūbu

Hokkaido Region, Hokkaido

Kanto Region, Kanto

Kinki Region, Kinki

Kyushu Region, Kyushu

Shikoku Region, Shikoku

Tohoku Region, Tōhoku